{"entity":{"id":"os-151","kind":"drug","name":"OS-151","aka":["rBCG-STING"],"tldr":"OS-151 is an experimental modified BCG from OncoSTING for bladder cancer, built to release an immune-activating molecule. It is in laboratory testing.","summary":"OS-151 is the lead product of OncoSTING, a second-generation BCG for non-muscle invasive bladder cancer that produces a STING agonist; the NIH RePORTER abstract describes the strain as overexpressing c-di-AMP. OncoSTING also plans intratumoral use in other solid tumours. Evidence is preclinical.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"OncoSTING: technology","url":"https://www.oncosting.com/technology"},{"label":"NIH RePORTER: SBIR award 1R44CA310037-01","url":"https://reporter.nih.gov/project-details/11312959"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["sting-agonist"],"targets":[],"drugs":[],"companies":["oncosting"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"OS-151","modality":"Recombinant BCG immunotherapy","mechanism":"A recombinant Bacillus Calmette-Guerin strain that overexpresses c-di-AMP, a STING agonist, to add STING-driven innate immune activation to BCG's effect, as the developer's award abstract describes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/os-151/","neighbours":{"technology":[{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/"}],"company":[{"id":"oncosting","kind":"company","name":"OncoSTING","route":"/companies/oncosting/"}]}}